Last reviewed 2026-04-20 · How we verify

Ricridene (NIFURZIDE)

Phase 2 active Small molecule

Ricridene (generic name: NIFURZIDE) is a nifurzide drug. It is currently in Phase 2 development.

Nifurzide is thought to work by inhibiting bacterial enzymes, disrupting the bacterial cell's ability to produce energy.

Ricridene (Nifurzide) is a small molecule drug in the nifurzide class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand its clinical applications and safety profile. As a result, its commercial status and generic availability are also unclear.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NIFURZIDE
Drug class	nifurzide
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like tiny factories, using energy to function properly. Bacteria, on the other hand, have their own way of making energy. Nifurzide works by blocking the bacteria's energy-making machinery, ultimately killing the bacteria and helping to treat infections.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ricridene CI brief — competitive landscape report
Ricridene updates RSS · CI watch RSS

Frequently asked questions about Ricridene

What is Ricridene?

Ricridene (NIFURZIDE) is a nifurzide drug.

How does Ricridene work?

Nifurzide is thought to work by inhibiting bacterial enzymes, disrupting the bacterial cell's ability to produce energy.

What is the generic name of Ricridene?

NIFURZIDE is the generic (nonproprietary) name of Ricridene.

What drug class is Ricridene in?

Ricridene belongs to the nifurzide class. See all nifurzide drugs at /class/nifurzide.

What development phase is Ricridene in?

Ricridene is in Phase 2.

Drug class: All nifurzide drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing